Budesonide Market Trends That Will Shape the Next Decade: Insights from Market Growth Driven By Innovations In Oral And Inhaled Therapies

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Budesonide Market Size By 2025?
The market size for budesonide has experienced robust growth in the past few years. It is projected to increase from $9.72 billion in 2024 to $10.26 billion in 2025, signifying a compound annual growth rate (CAGR) of 5.6%. Factors contributing to growth during the historic period include the escalating prevalence of respiratory conditions, heightened consciousness about inhaled corticosteroids, the debut of combination therapies involving budesonide, growth in healthcare accessibility and infrastructure, and the utilization of budesonide in off-label usage for inflammatory bowel diseases.

How Big Is the Budesonide Market Size Expected to Grow by 2029?
The budesonide market is predicted to experience substantial growth in the coming years, expanding to "$12.95 billion in 2029 at a 6.0% compound annual growth rate (CAGR). This expansion over the forecast period can be credited to the increasing need for effective treatment options, the creation of innovative drug delivery systems, the escalated use of budesonide, the growing elderly population who are susceptible to asthma, and the proliferation of generic budesonide products. Key trends during the forecast period encompass the acceptance of biologics and biosimilars, breakthroughs in drug delivery systems, regulatory endorsements for new formulations, the emergence of novel drug delivery systems, and advancements in technology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report

Which Key Market Drivers Powering Budesonide Market Expansion and Growth?
The burgeoning occurrence of respiratory diseases is anticipated to steamroll the expansion of the budesonide market in the future. These diseases are medical conditions that impair the organs and tissues involved in gas exchange in organisms breathing air. The escalating incidence of respiratory diseases is attributed to the increasing level of air pollution, primarily exposure to particulate matter and allergens, profoundly influencing the occurrence of asthma and chronic obstructive lung disease. Budesonide serves as a treatment for respiratory illnesses such as asthma and chronic obstructive pulmonary ailment (COPD), functioning to decrease inflammation, augment airflow, and forestall symptoms such as wheezing and breathing difficulty. To illustrate, as per the National Center for Health Statistics (NCHS), a US-based health statistics institution, the instance of current asthma among adults of 18 years and above surged from 8.4% in 2021 to 8.7% in 2022, as reported in May 2024. Furthermore, the rate of recent asthma attacks experienced by adults in the same demographic during the last 12 months also increased from 3.3% in 2021 to 3.7% in 2022. Consequently, the escalating incidence of respiratory diseases will accelerate the growth of the budesonide market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp

What Long-Term Trends Will Define the Future of the Budesonide Market?
Leading companies in the budesonide market are directing their efforts towards progress in respiratory disease treatment. This entails the development of oral therapy and enhancing patient experience, improving adherence to treatment, and broadening the range of therapeutic options for asthma and other respiratory ailments. Budesonide oral therapy, a formulation that is ingested rather than inhaled, is primarily employed for the treatment of inflammatory diseases. For example, Takeda Pharmaceuticals, a Japanese firm, announced in February 2024 that its EOHILIA, a budesonide oral suspension, has been given authorization by the American Food and Drug Administration (FDA) as the first and only FDA-approved oral medication for patients 11 years and older suffering from eosinophilic esophagitis (EoE). Furthermore, the FDA greenlit twice daily EOHILIA 2 mg based on the evidence of effectiveness and safety, acquired from two multi-centered, randomized, double-blind, placebo-controlled trials over twelve weeks, with participants aged 11 to 56 diagnosed with EoE.

What Are the Emerging Segments in the Budesonide Market?
The budesonide market covered in this report is segmented -

1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications

Subsegments:
1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)
2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers
3) By Injectable Suspension: Pre-filled Syringes, Vials
4) By Tablets And Capsules: Oral Tablets, Oral Capsules

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21121&type=smp

Who Are the Global Leaders in the Budesonide Market?
Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.

Which are the Top Profitable Regional Markets for the Budesonide Industry?
North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21121

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.